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ABSTRACT 
Objective: The objective of present work was to develop and validate simple, precise, accurate and specific stability indicating method for 
determination of acotiamide in presence of its degradation products. 
Methods: An isocratic RP-HPLC method has been developed using C-8 Thermo Hypersil BDS Column (250 x 4.6 mm i.d., 5µparticle size) with the 
mobile phase composition of acetonitrile: 0.1 % triethylamine in 0.2% formic acid (30: 70) at column oven temperature of 40 °C. The flow rate was 
1.0 ml min-1 and effluent was detected at 282 nm. The method was validated in terms of linearity, accuracy, precision, LOD (Limit of Detection), LOQ 
(Limit of Quantification) and robustness as per ICH guidelines. 
Results: The method was found to be linear in the range of 10-60µg/ml. Limit of detection and limit of quantification was found to 0.36µg/ml and 
1.10 µg/ml.% Recovery was found to be in the range of 99.45%-99.75%and precision less than 2%. The developed method was successfully applied 
for estimation of Acotiamide in marketed tablet formulation and percentage assay was found to be 100.45%. Acotiamide was subjected to stress 
degradation under acid, base, neutral hydrolysis, oxidation, dry heat, photolysis conditions. Significant degradation was observed in acid and base 
degradation. 
Conclusion: The developed RP-HPLC method was simple, rapid, accurate, precise and stability indicating for the estimation of Acotiamide in bulk 
and tablet dosage form. 
Keywords: Acotiamide, Reverse Phase High Performance Liquid Chromatography(RP HPLC), Stability Indicating Assay Methods (SIAM’s), Stress 
Degradation, ICH Q1A(R2), Q2R1 




Acotiamide (ACOT) is N-[2-[di(propane-2-yl)amino]ethyl]-2-[(2-
hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide; 
trihydrate; hydrochloride. Acotiamide is a new prokinetic agent [1]. 
It is approved in Japan in 2013 [2]. It causes an increase in the 
release of acetylcholine thereby it exerts gastroprokinetic activity 
through acting as an antagonist on the M1 and M2 muscarinic 
receptors in the enteric nervous system. It inhibits 
anticholinesterase activity. It may also act directly on the gut and 
indirectly on the central nervous system by way of brain-gut axis. 
Studies have shown that acotiamide could enhance gastric emptying 
and gastric accommodation. Acotiamide could be a promising agent 
in the treatments with functional dyspepsia [3, 4]. 
 
 
Fig. 1: Structure of acotiamide 
 
The presence of impurities can have a significant impact on the 
product quality, safety and efficacy, hence the percentage level of 
impurities need to control in the drug substance as well as a drug 
product. Information on the stability of molecule aids in the 
selection of proper storage conditions which is the pre-requisite of 
documentation of drug profile. Force degradation study is an 
important parameter in pharmaceutical research and development 
to predict stability of drug. Stress testing helps in identification of 
degradation products and degradation behaviour of drug [5, 6]. The 
literature reveals there were few analytical methods available for 
determination of acotiamide by HPLC [7], LC-MS-MS [8], UPLC-Q-
TOF-MS [9, 10], stability indicating the method by UPLC-Q-TOF-MS 
(gradient mode) [11], this reported method based on UPLC method. 
In the present study, a simple, rapid, precise, isocratic, accurate, 
cost-effective stability indicating liquid chromatographic method 
was developed by HPLC for the determination of Acotiamide in 
tablet dosage forms and validated as per ICH guidelines [12, 13]. 
MATERIALS AND METHODS  
Chemicals, reagents and solutions 
Acotiamide hydrochloride trihydrate (ACOT) bulk drug was 
provided by Hetero Drugs Pvt. Ltd. Acogut tablets 100 mg were 
purchased from local pharmacy. HPLC grade methanol and 
acetonitrile were purchased from Rankem Ltd, Mumbai. HPLC grade 
triethylamine and formic acid were purchased from Loba Chemie 
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Pvt. Ltd, Mumbai. Hydrochloric acid (HCl), sodium hydroxide 
(NaOH) and hydrogen peroxide (H2O2) were purchased from SD Fine 
Chem. Ltd. Mumbai, India. 
Preparation of mobile phase buffer  
The buffer was prepared by adding 1 ml of triethylamine in 1000 ml 
of double distilled water and adjusting the pH with 2 ml of formic 
acid. 
Mobile phase composition  
The mobile phase was prepared using buffer and acetonitrile in the 
ratio of 70:30. Before use, the mobile phase was filtered through 
0.2µ nylon membrane filter and sonicated for 5 min. 
Instrumentation and chromatographic conditions 
HPLC-PDA 
Analytical Chromatography was performed on Waters Alliance 2695 
separation module, Waters 2996 Photo Diode Array Detector (PDA). 
Data acquisition and integration were performed using Emchem 2 
software. Chromatographic separation of ACOT was achieved at 
column oven temperature of 40 °C using C-8 Thermo Hypersil BDS 
column (250 X 4.6 mm i.d., 5 µ particle size) with mobile phase 
composition of acetonitrile: 0.1% triethylamine with 0.2% formic acid 
(30:70). The flow rate was at 1.0 ml min-1 and effluent was detected at 
282 nm.  
Preparation of standard stock solution 
ACOT stock solution (1000 µg/ml) was prepared by dissolving 25 
mg of ACOT in 25 ml of double distilled water and acetonitrile 
(70:30) in 25 ml of volumetric flask. 
Preparation of working standard solution 
ACOT working solution (100 µg/ml) was prepared by transferring 
2.5 ml from a stock solution to 25 ml volumetric flask and diluted up 
to the mark with mobile phase. 
Construction of calibration curve  
Aliquots ranging from 0.5 ml to 3.0 ml were taken, from standard 
stock solution in 10 ml volumetric flask and diluted to 10 ml with 
mobile phase to give a final concentration of 5, 10, 15, 20, 25, 30µg 
ml-1. 20 µl of each concentration was injected in the 
chromatographic system and the chromatogram was recorded. A 
calibration curve was constructed by plotting peak area versus 
concentration of drug and regression equation was calculated.  
Preparation of test sample solution  
20 tablets were crushed using mortar-pestle, the powder was 
weighed and quantity of powder equivalent to 25 mg of ACOT was 
transferred in 25 ml volumetric flask, dissolved in a solvent (water: 
acetonitrile 70:30) and sonicated for 30 min. The solution was 
filtered through 0.45 µ Nylon 6,6 syringe filter. 2 ml was transferred 
in 10 ml volumetric flask and volume were adjusted upto the mark 
with mobile phase to give a concentration of 20µg/ml of ACOT. 
Method validation 
The proposed method was validated according to the ICH guidelines 
[12] for system suitability, linearity, precision, recovery, limit of 
detection (LOD) and limit of quantitation (LOQ), robustness, 
specificity. 
System suitability 
System suitability test should be carried out to verify that the 
analytical system is working properly and can give accurate and 
precise results. Working standard solutions were prepared and 
injected six times into the chromatographic system. The system 
suitability parameters were evaluated for peak area, retention time, 
tailing factor and theoretical plates of the standard chromatogram. 
Linearity and range 
The linearity of the method was evaluated thrice by analyzing the 
prepared concentration of ACOT in the range of 5-30 µg/ml from the 
stock solution. 20 µl of each solution was injected into HPLC system 
and the peak area of chromatogram was noted. Linear regression 
was obtained over the concentration range (y=mx+c). 
Precision 
The intra-day precision of the assay method was evaluated at six 
concentration levels (5-30µg/ml) (n=6) against a qualified reference 
standard. % RSD of the three obtained assay values at six different 
concentration levels was calculated. The inter-day precision study 
was performed in three different days at six different concentration 
levels (5-30µg/ml) and each value is the average of the three 
determinations (n=3). The % RSD of the three obtained assay values 
on three different days was calculated. 
Accuracy 
The % recovery was performed by standard addition method. In this 
method, fixed amount of sample solution of ACOT and increasing 
amount of its working standard solutions were added at 80,100 and 
120% level of pure drug solution. Standard addition and recovery 
experiments were conducted to determine the accuracy of the 
method for the quantitation of ACOT in the drug product. 
Limit of detection and limit of quantification (LOQ) 
The limit of detection (LOD) and limit of quantification (LOQ) were 
calculated by the following formula:  
Limit of detection =3.3*σ/S 
Limit of quantification = 10*σ/S 
Where σ is the standard deviation of y-intercept and S is the slope of 
the calibration curve 
Robustness  
The robustness of the assay method was calculated by introducing small 
changes in the HPLC condition which included pH of the buffer (2.8,3.2), 
flow rate (0.9 and 1.1 ml/min), the percentage of acetonitrile in the 
mobile phase (28 and 32). Robustness of the method was studied using 
three replicates at a concentration level of 15µg/ml of ACOT. 
Specificity 
Specificity is the ability of the method to measure an analyte in 
presence of its degradation products. ACOT was subjected to various 
stress conditions like hydrolytic, oxidative, thermal and photolytic. 
Degraded samples were injected into HPLC system and developed 
chromatograms were observed for resolution of degraded products. 
Force degradation study [14-16] 
A stock solution of ACOT was prepared by dissolving 25 mg of ACOT 
in 25 ml of double distilled water. This stock solution was used for 
degradation studies. 
Hydrolytic conditions  
Acid degradation 
5 ml of stock solution of ACOT was taken in 25 ml of volumetric 
flask, 1 ml of 1N HCl was added and the solution was heated in a 
water bath at 100 °C for 3 h. The solution was cooled and 
neutralized with 1N NaOH. Volume was made up to 25 ml with 
water to make the concentration of 200µg/ml. The solution was 
filtered through 0.45 µ Nylon 6,6 membrane syringe filter. 
Base degradation  
5 ml of stock solution of ACOT was taken in 25 ml of volumetric 
flask, 1 ml of 0.5 N NaOH was added and the solution was heated in a 
water bath at 100 °C for 3 h. The solution was cooled and 
neutralized with 0.5 N HCl. Volume was made up to 25 ml with 
water to make the concentration of 200µg/ml. The solution was 
filtered through 0.45 µ Nylon 6,6 membrane syringe filter. 
Water degradation 
5 ml of stock solution of ACOT was taken in 25 ml of volumetric 
flask, 1 ml of water was added and the solution was heated in a 
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water bath at 100 °C for 6 h. The solution was cooled. Volume was 
made upto 25 ml with water to make the concentration of 
200µg/ml. The solution was filtered through 0.45µ membrane 
syringe filter. 
Oxidizing conditions  
Hydrogen peroxide-induced degradation 5 ml of stock solution of 
ACOT was taken in 25 ml of volumetric flask, 1 ml of 6% hydrogen 
peroxide was added. The solution was kept at room temperature for 
48 h. The solution was made upto volume with water. The solution 
was filtered through 0.45 µ Nylon 6,6 membrane syringe filter. 
Thermal conditions  
Dry heat 25 mg of ACOT was placed in an oven at 80˚C for 8 d under 
dry heat condition in the dark and then cooled to room temperature. 
Volume was made with water to get a concentration of 200µg/ml. 
Photolytic degradation 
For the photochemical study, ACOT equivalent to 25 mg was spread 
in 1 mm thickness on a petridish and exposed to 5383 LUX and 144 
UV/cm2 for 8 d and volume was made up to 25 ml with water. 5 ml 
of the solution was taken and further diluted upto 25 ml with water 
to make the concentration of 200µg/ml. 
 
Table 1: Stress conditions for forced degradation study of ACOT 
Stress condition Solvent Temperature Time 
Hydrolytic    
Acid 1 N HCl 100˚C 3 h 
Base 0.5 N NaOH 100˚C 3 h 
Neutral Water 100˚C 6 h 
Oxidative 6% H2O2 RT 48 h 
Thermal    
Dry Heat --- 80˚C 8 d 
Photolytic --- 5382LUX and 144UV/cm2 10 d 
 
RESULTS  
Method development and optimization  
A detection wavelength 282 nm was selected from the range UV spectral 
data due to its high sensitivity for all degradation products and minimal 
difference in response factors. ACOT having pKa 10.24, pH 3.0 buffer was 
selected to enable better column performance. Isocratic run was 
accessed using mobile phase 0.1% triethylamine adjusted to pH 3 with 
0.2 % formic acid and acetonitrile (70:30) on C-8 and C-18 column. 
Column C-8 with column oven temperature of 40 °C provided the highest 
number of peaks and better resolution. Thus, further experiments were 
carried out using thermo hypersil BDS C8 column. 
Method validation 
System suitability method 
The developed method has produced theoretical plates more than 
2000 with tailing factor less than 2. The % RSD of peak area was less 
than 2 which ensured the suitability of the developed method. The 
results of the system suitability study are summarised in table 2. 
 
Table 2: System suitability parameters of ACOT 
Parameters mean±SD 
Retention Time 9.387±0.057 
Theoretical Plates 12098±21.36 
Tailing factor 1.047±0.043 
Peak Area 762504±0.495 
 
Linearity and range 
In the proposed validation method, the retention time of ACOT was 
9.3 min. The calibration curve for ACOT was constructed by plotting 
area versus their corresponding concentrations, linearity was found 
over the range 5-30µg/ml with a coefficient of relation (R2). Results 
of linearity are shown in fig. 2 and table 3. 
Detection and quantification limits 
According to the pharmaceutical recommendations, limit of 
detection (LOD) and limit of quantification (LOQ) were determined, 
at the signal to noise ratios of 3:1 and 10:1, respectively. Limit of 
detection of ACOT was found to be 0.36µg/ml. Limit of 
quantification of ACOT was found to be 1.10µg/ml. 
  
Table 3: Calibration curve of ACOT 
Level Concentration (µg/ml) Area 
1 5 150914 
2 10 361779 
3 15 568471 
4 20 771652 
5 25 945829 
6 30 1180668 
 
Precision and accuracy  
The within-day (intra-day) precision and accuracy for the proposed 
method were studied at three concentration levels of ACOT using 
three replicate determinations for each concentration within one 
day. Similarly, the between-day (inter-day) precision and accuracy 
were tested by analyzing the same three concentrations using three 
replicate determinations repeated on three days. Recoveries were 
calculated using the regression equation and they were satisfactory. 
The percentage of relative standard deviation (%RSD) was less than 
1.5% providing the high repeatability, intermediate precision and 
accuracy of the developed method for the estimation of ACOT in bulk 
form. Results of precision are shown in table 4, 5. Results of recovery 
are shown in table 6. 
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Fig. 2: Calibration curve of ACOT 
 
Table 4: Intra-day precision of ACOT (n=3) 
Concentration (µg/ml) Area (mean±SD) %RSD Retention time (mean±SD) %RSD 
10 352540±4129.327 1.171 9.608±0.085 0.891 
20 764518.3±3789.857± 0.495 9.644±0.040 0.417 
30 1189078±14035.98 1.180 9.652±0.022 0.232 
n= number of determinations, SD =Standard Deviation, %RSD = % Relative Standard Deviation 
 
Table 5: Inter-day precision of ACOT (n=3) 
Concentration (µg/ml) Area (mean±SD) % RSD Retention time (mean±SD) %RSD 
10 366767±6371.719 1.737 9.613±0.078 0.817 
20 772256±8524.635 1.103 9.609±0.043 0.453 
30 1200857±16000.6 1.332 9.637±0.040 0.421 
n= number of determinations, SD =Standard Deviation, %RSD = % Relative Standard Deviation 
 
Table 6: Recovery studies of ACOT (n=3) 
Concentration 
(µg/ml) 
Amt of ACOT added 
(µg/ml) 








20 10 9.972 9.93±0.04 0.40 99.72 99.3±0.40 0.40 
20 20 19.938 19.8±0.12 0.63 99.69 99.3±0.29 0.29 
20 30 29.847 29.6±0.15 0.57 99.49 98.9±0.51 0.52 
n= number of determinations, SD =Standard Deviation, %RSD = % Relative Standard Deviation 
 
Robustness 
The robustness was examined by evaluating the influence of 
small variations in different conditions such as flow rate, 
detection wavelength and organic ratio. The average value of 
%RSD for determination of ACOT less than 2% revealed 
robustness of the method. Results of robustness studies are 
shown in table 7. 
 
Table 7: Robustness studies of ACOT (n=3) 
Flow rate Area (mean±SD) % RSD Retention time (mean±SD) %RSD 
0.9 571144.3±7238.28 1.267 11.39333±0.06 0.566 
1 570358.3±8351.74 1.464 9.606333±0.02 0.282 
1.1 573424.3±7510.62 1.309 8.342667±0.02 0.306 
Organic ratio acetonitrile Area (mean±SD) %RSD Retention Time (mean±SD) %RSD 
28 577713.7±4829.15 0.835 11.41633±0.10 0.911 
30 578040.3±5985.97 1.035 9.631667±0.01 0.176 
32 567522.3±5833.48 1.027 8.592333±0.07 0.852 
Wavelength Area (mean±SD) % RSD Retention Time (mean±SD) %RSD 
281 578040.3±7076.25 1.224 9.521±0.008 0.084 
282 581313.7±7879.20 1.355 9.505±0.072 0.760 
283 568682±5850.65 1.028 9.510±0.017 0.179 
n= number of determinations, SD =Standard Deviation, %RSD = % Relative Standard Deviation 
 
Stability of solutions 
Solutions containing different concentrations of ACOT were prepared 
from standard solution and stored at room temperature for 24 h. They 
were then injected into LC system. No additional peaks were found in 
chromatogram and area under the peak comes within 2%. 
Filter compatibility 
Filter compatibility was performed on 0.45 µNylon 6,6 syringe 
filter,0.45µ PTFE hydrophilic syringe filter and 0.45 µ PTFE 
hydrophobic syringe filter. Filter compatibility study was done by % 
recovery method. The sample was filtered through syringe filters 
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and percentage assay was calculated and variation in the assay value 
was compared against the centrifuged sample. Results are shown in 
table 8. After analysis, it was found that Nylon 6,6 syringe filter and 
PTFE hydrophilic syringe filter were suitable for filtration. 
 
Table 8: Filter compatibility study 
Sample name  Peak area  % difference 
Standard sample 771427 --- 
Sample filtered through 0.45µ Nylon 6,6 syringe filter 770936 0.2 
Sample filtered through 0.45 µ PTFE hydrophilic syringe filter 768234 0.5 
Sample filtered through 0.45µ PTFE hydrophobic syringe filter 793456 2.8 
 
Force degradation study 
The results from the stress testing studies indicate that the 
method is highly specific for ACOT. Degradation products were 
completely distinguishable from the parent compound. The drug 
undergoes significant degradation under acid, alkaline conditions. 
Alkaline degradation was faster than acidic degradation. The drug 
was relatively stable in oxidative neutral, dry heat and photolytic 
degradation. Three degradation products were obtained in 
alkaline hydrolysis. In alkaline hydrolysis, degradation peaks were 
obtained at RT of 3.7, 4.5 and 6.8 min on heating. One degradation 
product was obtained in acid hydrolysis at RT of 5.3 min. The 




Fig. 3: Chromatogram of ACOT (200 ppm) 
 
 
Fig. 4: Degradation of ACOT in 1 N HCl at 100 ° C for 3 h 
 
 
Fig. 5: Degradation of ACOT in 0.5 M NaOH at 100˚C for 3 h (Zoomed view) 
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Fig. 6: Degradation of ACOT in 0.5 M NaOH at 100˚C for 3 h (Full view) 
 
 
Fig. 7: Degradation of ACOT in 6% H2O2 at room temperature for 48 h 
 
 
Fig. 8: Degradation of ACOT in thermal at 80˚c for 8 d 
 
 
Fig. 9: Degradation of ACOT in photolytic condition dry for 11 d 
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Fig. 10: Degradation of ACOT in photolytic solution for 11 d 
 
Table 9: Data of forced degradation studies of ACOT 
Conditions  % degradation 
in API 
% API % degradation in 
formulation 








Acidic 1N HCl at 100 
°C for 3 h 
0.96% 99.3% 0.7% 99.3% 1 5.300 
Alkaline 0.5 N NaOH at 
100 °C for 3 h 
15.2% 84.7% 14.7% 85.3% 3 3.591 
4.709 
5.129 
Oxidation 6% H2O2 for 48 
h at RT 
No degradation 99.2 
% 
No degradation 99.5 % - - 
Thermal Dry at 80 °C for 
8 d 
No degradation 99.8% No degradation 99.7% - - 
 Solution at 80 
°C for 8 d 
No degradation 99.5 
% 
No degradation 99.7 % - - 
Photolytic Dry for 11 d No degradation 99.5 
% 
No degradation 99.8 % - - 
 Solution for 11 
d 
No degradation 99.7 
% 
No degradation 99.8 % - - 
 
DISCUSSION  
The ICH Q1A [13] guideline suggests that stability indicating method 
must be performed to monitor the properties of drug substance 
which are likely to change during storage and which are likely to 
affect quality, the efficacy of the formulation. 
During development of stability indicating method, in alkaline 
degradation conditions for separation of degradation products from 
ACOT, trials were taken with mobile phase 0.1 % formic acid: 
methanol, 0.1 % formic acid: acetonitrile on C-18 column and C-8 
column. Degradation peaks were resolved from ACOT on C-8 column 
with column oven temperature of 40 °C with a mobile phase of 0.1 % 
triethylamine in 0.2 % formic acid: acetonitrile in the ratio of 70:30. 
The retention time of ACOT was 9.387 min. Detection was done at 
282 nm. The method was validated according to ICH guidelines. The 
linearity of ACOT was found to be in the range of 5-30µg/ml with a 
correlation coefficient of 0.999.% Recovery was found to be 98.9-
99.3%. Significant degradation was observed in alkaline conditions 
with three degradation products and in acidic conditions, one 
degradation product is formed. The reported method [11] is 
developed on UPLC, with cyano column. Those facilities as UPLC 
instrument and cyano column both are rarely available in University 
or institute. The degradation conditions in the reported methods are 
harsh conditions. Our method is developed by HPLC method on C-8 
column. The developed method is simple, precise, isocratic, accurate, 
robust, cost-effective and with available facilities in common 
laboratories in absence of advanced facilities and instrument. 
CONCLUSION 
A simple, specific, accurate, precise stability indicating method has 
developed. The proposed method presented the ability to separate 
ACOT from all its degradation products and therefore can be applied 
instability testing of the commercially available formulation. 
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